A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

计划入组 360 人 · 首次发布于 2026 年 6 月 4 日

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

计划入组 450 人 · 首次发布于 2025 年 4 月 6 日

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

计划入组 148 人 · 首次发布于 2025 年 1 月 8 日

BAY-1165747

BAY-1161116

BAY-946

BAY PATH UNIVERSITY

United States

Sutter Bay Hospitals

United States

Kips Bay Medical, Inc.

United States

Bayer Launches Global Phase II Trial of GIRK4 Inhibitor BAY 3670549 in Atrial Fibrillation

Atrial Fibrillation Pipeline Shows Robust Development with 15+ Novel Therapies from Leading Pharmaceutical Companies

BAY 2927088 Demonstrates Promising Activity in HER2-Mutant NSCLC